{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:13:13Z","timestamp":1790190793489,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.03052","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T05:03:04Z","timestamp":1578632584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":86,"title":["Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis"],"prefix":"10.3389","volume":"10","author":[{"given":"Karissa L.","family":"Gable","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1212\/01.CON.0000455873.30438.9b","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"20","author":"Sanders","year":"2014","journal-title":"Continuum (Minneap Minn)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00004691-199304000-00004","article-title":"Clinical neurophysiology of disorders of the neuromuscular junction","volume":"10","author":"Sanders","year":"1993","journal-title":"J Clin Neurophysiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transf Med Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1053\/j.ajkd.2008.02.360","article-title":"Therapeutic plasma exchange: core curriculum 2008","volume":"52","author":"Kaplan","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jca.21257","article-title":"Therapeutic plasma exchange: a technical and operational review","volume":"28","author":"Kaplan","year":"2013","journal-title":"J Clin Apheresis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/intimm\/10.9.1289","article-title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice","volume":"10","author":"Borvak","year":"1998","journal-title":"Int Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0020-708X(56)90020-5","article-title":"Behaviour of 14C- and 131I-labelled plasma proteins in the rat","volume":"1","author":"Campbell","year":"1956","journal-title":"Int J Appl Radiat Isot."},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1749-6632.1957.tb35374.x","article-title":"The behavior of I 131-labeled plasma proteins in vivo","volume":"70","author":"Mc","year":"1957","journal-title":"Ann N Y Acad Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/bj0760475","article-title":"Metabolic heterogeneity of human gamma-globulin","volume":"76","author":"Cohen","year":"1960","journal-title":"Biochem J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"282989","DOI":"10.1155\/2012\/282989","article-title":"Pharmacokinetic models for FcRn-mediated IgG disposition","volume":"2012","author":"Xiao","year":"2012","journal-title":"J Biomed Biotechnol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsoon","year":"2014","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Ameloriation of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Huijbers","year":"2019","journal-title":"Exp Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal Fc Receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"498 e1","DOI":"10.1016\/j.ajog.2019.02.058","article-title":"M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model","volume":"220","author":"Roy","year":"2019","journal-title":"Am J Obstet Gynecol."},{"key":"B24","unstructured":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)2019"},{"key":"B25","unstructured":"Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results2019"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration","volume-title":"2019 American Academy of Neurology Annual Meeting","author":"Collins","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"key":"B28","article-title":"Efgartigimod in myasthenia gravis: update on clinical development and phase 3 ADAPT study","volume-title":"2019 Muscle Study Group Meeting","author":"Ulrichts","year":"2019"},{"key":"B29","unstructured":"An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)2018"},{"key":"B30","unstructured":"Pharmaceuticals, IncA Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis2018"},{"key":"B31","unstructured":"UCBPharma Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis2017"},{"key":"B32","unstructured":"UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase2018"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S43.001","article-title":"Proof-of-concept and safety of the anti-FcRn antibody rozanolixizumab in patients with moderate-to-severe generalized myasthenia gravis (GMG): a phase 2a study","volume-title":"2019 American Academy of Neurology Annual Meeting","author":"Bril","year":"2019"},{"key":"B34","unstructured":"study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis2019"},{"key":"B35","unstructured":"Sciences GmbHA Study of RVT-1401 in Myasthenia Gravis (MG) Patients2019"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Ann Clin Transl Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T23:14:45Z","timestamp":1722294885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2019.03052"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.03052","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"article-number":"3052"}}